Company Filing History:
3 out of 8 
2 out of 19 
1 out of 35 Years Active: 2019-2024
Title: The Innovations of Michael Allen Flynn
Introduction
Michael Allen Flynn is a notable inventor based in Ann Arbor, MI, who has made significant contributions to the field of biomedical innovation. With a total of six patents to his name, Flynn is recognized for his groundbreaking work in ocular treatments, particularly those targeting conditions associated with angiogenesis.
Latest Patents
Flynn's latest patents include innovative methods of treating ocular conditions by administering humanized monoclonal antibodies that target VE-PTP (HPTP-Beta). This disclosure outlines compositions and methods specifically aimed at the treatment of ocular conditions linked to angiogenesis, focusing on the administration of antibodies that inhibit tyrosine phosphatase in affected subjects. These inventive methods showcase Flynn's dedication to advancing healthcare solutions.
Career Highlights
Throughout his career, Flynn has worked with prominent companies in the pharmaceutical industry, including Aerpio Pharmaceuticals, Inc. and Eyepoint Pharmaceuticals, Inc. His experience in these organizations highlights his role in developing treatments that have the potential to greatly improve patient outcomes.
Collaborations
Flynn’s work has often involved collaboration with other talented professionals, including Kevin Gene Peters. Such partnerships in the research and development process have likely played a crucial role in advancing his innovative ideas and patents.
Conclusion
Michael Allen Flynn stands out as an influential inventor in the realm of ocular treatments. His continued efforts in developing monoclonal antibody therapies reflect a commitment to innovation and the improvement of medical care. As he advances his research and application of his inventions, the impact of his work is expected to resonate within the medical community and beyond.